Before a foreign manufacturer can think about NMPA registration timelines or dossier structure, two foundational questions must be answered: Which standards apply to my device, and which class is my device? Get either question wrong, and the entire registration strategy is built on sand.

China's standards and classification frameworks are more dynamic than most foreign teams realize. The classification catalogue is updated regularly, mandatory standards lists are revised, and a major legislative overhaul — the Medical Device Management Law — is in active development and could reshape how industry standards function. This guide draws on insights from our team's experience as former NMPA review specialists to give you a working understanding of both systems.

1. The Regulatory Foundation: Who Manages What

China's medical device regulatory system operates under a comprehensive framework centered on the National Medical Products Administration (NMPA, 国家药品监督管理局). The scope covers everything from research and manufacturing through distribution and clinical use — a full lifecycle, full supply chain mandate.

Three administrative certificates define market access:

• Product Registration or Filing Certificate (产品注册/备案证) — confirms the device meets technical standards and is approved for market
• Manufacturing License (生产许可证) — authorizes the facility to manufacture the registered device
• Distribution License (经营许可证) — required for distributors of Class II and Class III devices in China

For foreign manufacturers, the product registration certificate is the primary focus. The manufacturing license is issued by the home country authority and recognized via a quality management system certification (ISO 13485). The distribution license is your Chinese distributor's responsibility.

2. China's Medical Device Standards System

Legal Definition and Authority

Under the Medical Device Standards Management Measures (医疗器械标准管理办法), a medical device standard is a unified technical requirement organized and issued by NMPA in accordance with legal procedures, to be followed across the research, manufacturing, distribution, use, and supervision of medical devices.

The key legal provision is Article 7 of the MDSAM Regulations: medical device products must comply with mandatory national standards (强制性国家标准); where no mandatory national standard exists, they must comply with mandatory industry standards (强制性行业标准).

Two Dimensions of Standards Classification

China's medical device standards are organized along two axes:

By legal effect:

• Mandatory standards (强制性标准) — protect human health and life safety. Compliance is legally required for all applicable devices.
• Recommended standards (推荐性标准) — voluntary, but carry significant practical weight. If cited in a registration dossier, NMPA verifies compliance.

By subject matter:

• Basic standards (基础标准) — terminology, symbols, general principles
• Method standards (方法标准) — test methods, measurement procedures
• Management standards (管理标准) — quality systems, post-market surveillance requirements
• Product standards (产品标准) — device-specific performance and safety requirements

Standards also sit at two levels: national standards (GB/YY — 国家标准) and industry standards (YY — 行业标准). National standards have broader authority; industry standards fill gaps for specific device categories.

Standards Governance Structure

The National Medical Device Standards Committee (国家医疗器械标准委员会), established under NMPA and the national standards authority, oversees standards planning and implementation across all technical domains. Multiple specialized subcommittees handle specific device categories — from cardiovascular implants to in vitro diagnostics to software as a medical device.

Foreign manufacturers engaging with Chinese standards need to understand that the technical content often mirrors — but does not identical-map to — international standards (ISO, IEC, ASTM). China harmonizes extensively but also adds or modifies requirements to reflect domestic clinical practice and regulatory priorities. Always verify the current Chinese version of any standard rather than assuming it matches the international equivalent.

3. Mandatory Standards: What Compliance Actually Requires

NMPA publishes and periodically updates the Medical Device Product Mandatory Standards List (医疗器械产品适用强制性标准清单), most recently revised in 2024. This list maps device categories to their applicable mandatory standards and is essential reading before preparing any registration dossier.

What Registration Requires

During the dossier review (立卷审查), applicants must provide evidence of conformance for every applicable mandatory standard. Critically:

• The evidence is not limited to test reports — for standards with clinical trial, biological, or evaluative requirements, corresponding study data can serve as conformance evidence
• When a standard has been updated and a new version published, NMPA's review notes (以"注"的形式) clarify transition requirements — the applicant must check which version applies
• All applicable mandatory standards must be addressed — there is no option to omit a standard without documented justification

When Your Device Cannot Fully Comply

Products sometimes cannot meet every clause of a mandatory standard due to their design or intended use. In these situations, NMPA does not automatically reject the application, but expects a rigorous written justification that:

• Identifies the specific non-conforming clause(s)
• Explains why the clause is not applicable or cannot be met
• Provides equivalent safety evidence demonstrating the device does not pose the hazard the standard was designed to prevent

Submitting a dossier that simply marks a mandatory standard as "not applicable" without explanation is among the most reliable ways to receive a deficiency letter. NMPA reviewers are trained to identify this pattern.

Practical Example: Orthopedic Implants and Accelerated Aging

A common question involves whether the accelerated aging test in YY/T 0772.3 (for UHMWPE orthopedic implants) can substitute for the product stability study required in the registration dossier. NMPA's position is clear: these are distinct requirements. The YY/T 0772.3 aging protocol evaluates material properties but does not model real-world storage conditions. Product stability research — per the Guidance on Stability Research for Passive Implantable Medical Devices — requires either real-time or Arrhenius-modeled accelerated stability data that characterizes actual shelf-life degradation. Conflating the two is a frequent dossier error.

4. The Medical Device Classification System

Three Classes, Different Pathways

The Classification Catalogue (分类目录)

Classification in China is primarily determined by the Medical Device Classification Catalogue (医疗器械分类目录), organized into 22 subdirectories covering all major device categories. Each entry specifies:

• First-level and second-level product categories
• Product description
• Intended use
• Management class (I, II, or III)
• Representative product name examples

The catalogue is dynamically updated. Since its major revision, NMPA has issued multiple adjustment announcements (2020 No. 47, 2022 No. 25, 2022 No. 30, 2023 No. 101) that have added, removed, or reclassified product categories. Manufacturers should always verify they are working against the current version.

Dynamic adjustments can include:

• Modifying subdirectory structure or product category names
• Changing the management class of existing product types
• Adding representative innovative devices that have been approved
• Removing products no longer regulated as medical devices
• Updating product descriptions, intended use language, or product name examples

Classification Rules (分类规则)

The Medical Device Classification Rules (医疗器械分类规则) provide the principles for determining classification when the catalogue does not provide a clear answer. They define factors such as the degree of invasiveness, duration of contact, whether the device is active or passive, and whether it incorporates a medicinal substance. Foreign manufacturers should understand these rules when dealing with novel or combination devices.

5. Classifying Novel Devices Not in the Catalogue

For devices not clearly covered by any catalogue entry, manufacturers have two options:

1. 1
   Apply Directly as Class III ("同三类") Submit directly under Class III registration procedures. NMPA will then independently assess the appropriate class — if reviewers determine the device is actually Class II or Class I, they will direct the applicant to the appropriate pathway. This route is permitted under the MDSAM Regulations and is often chosen when a manufacturer wants to move quickly.
2. 2
   Request a Classification Determination (分类界定申请) Submit a formal application to NMPA for a classification opinion. This requires product name, composition, mechanism of action, intended use, and supporting technical data. The determination provides regulatory certainty before the full registration process begins, which can prevent wasted dossier preparation effort.

Combination Devices: Classification Code Challenges

Active devices that integrate two distinct functional modules — each covered by different catalogue entries — present a common practical challenge for classification codes. NMPA's guidance is:

• The overall device class is determined by the higher-risk module's class
• For the classification code itself: if the device has a clear primary function, use that module's code. If primary function cannot be determined, either module's code may be used. A formal classification determination is not required in most cases.
• Example: An ultrasonic-radiofrequency combination surgical device combines ultrasound surgery (code 01-01-01) with high-frequency surgery (01-03-01) — both Class III under subdirectory 01. The combined device is Class III; the applicant may cite either code, or 01-00 if no primary function can be established.

6. Drug-Device Combination Products

When a product contains both a drug component and a device component, China's regulatory system routes it through a two-stage determination process:

Stage 1: Classification Determination (分类界定)

Is this product a medical device at all, or is it a drug? NMPA's classification determination system resolves this question. Example: NMPA determined in 2022 that medical radiation protection spray (医用射线防护喷剂) — containing SOD enzyme, curcumin, and other components, intended to protect skin from radiation-induced damage — is regulated as a Class II medical device.

Stage 2: Attribute Determination (属性界定)

If confirmed as a combination product, the attribute determination process establishes whether the product acts primarily as a drug or primarily as a device — which determines the regulatory pathway. This determination requires:

• Product name, composition, dosage, combination method, intended use, patient contact site and duration, product diagrams and photographs
• Domestic and international comparable product information (structure, composition, regulatory status)
• Mechanism of action analysis for the product and each component
• Applicant's proposed primary mode of action and supporting justification

If determined to be primarily a device, the product registers with NMPA under medical device regulations. If primarily a drug, it follows the drug registration pathway through the Center for Drug Evaluation (CDE). Appeals of attribute determinations can be requested within 10 working days.

7. What the Upcoming Medical Device Management Law Changes

China's current framework is built around the Medical Device Supervision and Administration Regulations (条例, an executive regulation). The draft Medical Device Management Law (医疗器械管理法, legislative law) is currently in public consultation and represents the most significant regulatory reform since 2021.

For the standards system, the most consequential proposed change is in Article 21 of the draft law: it references only national standards, dropping the existing fallback provision for mandatory industry standards.

Under current regulations (Article 7, MDSAM): devices must comply with mandatory national standards; where none exist, mandatory industry standards apply. The draft law removes this industry standard fallback entirely, referencing only national standards.

The draft law also establishes the National Medical Device Standards Committee with an explicit mandate to oversee standards planning and all specialized technical organizations — codifying at legislative level what has previously operated as an administrative structure.

8. Practical Implications for Foreign Manufacturers

Before You Start Your Dossier

• Confirm your device's current classification against the latest catalogue version — don't rely on a classification opinion from more than 12 months ago given the dynamic adjustment cycle
• Download the 2024 revised mandatory standards list for your device category and map each standard against your technical documentation
• Check standard versions — if a newer version of a mandatory standard has been published, NMPA may require conformance to the new version; the review notes will specify transition timelines
• Identify any recommended standards you intend to cite — once cited, you are held to them

During Dossier Preparation

• Address every applicable mandatory standard explicitly — even if the answer is a documented justification for non-applicability
• Do not conflate different types of studies (e.g., material characterization tests vs. shelf-life stability studies)
• Use current Chinese standard numbers and titles in your dossier — citing superseded standard numbers is a common translation error

Novel or Borderline Devices

• If your device is not clearly in the catalogue, consider the "apply as Class III" route for speed, or the formal classification determination route for certainty
• For drug-device combinations, engage the classification and attribute determination processes early — these add significant time and must be completed before registration

在讨论NMPA注册时间线或申报资料结构之前，有两个基础问题必须首先回答：我的产品适用哪些标准？我的产品属于哪类？这两个问题答错任何一个，整个注册策略都将建立在错误的基础上。

中国的标准和分类体系远比多数境外团队认为的更具动态性。分类目录定期更新，强制性标准目录持续修订，即将出台的《医疗器械管理法》可能从根本上改变行业标准的法律地位。

一、监管基础：管什么，谁来管，怎么管

中国医疗器械监管以国家药品监督管理局（NMPA）为核心，覆盖研制、生产、经营、使用的全链条、全生命周期。

市场准入涉及三类行政许可：

• 产品注册证/备案凭证——证明产品符合技术要求，获准上市
• 生产许可证——授权生产设施从事已注册产品的生产
• 经营许可证——二类、三类器械经营企业须持有

对境外制造商而言，产品注册证是核心。生产许可依托ISO 13485认证体现；经营许可是中国经销商的责任。

二、医疗器械标准体系

法律定义与效力

根据《医疗器械标准管理办法》，医疗器械标准是指由NMPA依职责组织制修订、依法定程序发布，在医疗器械研制、生产、经营、使用、监督管理等活动中遵循的统一技术要求。

关键法律条文是《医疗器械监督管理条例》第七条：医疗器械产品应当符合医疗器械强制性国家标准；尚无强制性国家标准的，应当符合医疗器械强制性行业标准。

标准的两个维度

按效力分：

• 强制性标准——保障人体健康和生命安全，产品必须符合，否则不予注册
• 推荐性标准——自愿执行，但实践中权重显著：一旦在申报资料中声明执行，NMPA将进行核查

按规范对象分：

• 基础标准——术语、符号、通用原则
• 方法标准——检测方法、测量程序
• 管理标准——质量管理体系、上市后监管要求
• 产品标准——特定器械的性能与安全要求

标准还分为国家标准（GB/YY）和行业标准（YY）两个层级。

标准技术组织架构

国家医疗器械标准委员会由NMPA会同国家标准化行政主管部门共同组建，统一负责医疗器械标准规划制定和组织实施，统筹管理各专业领域标准化技术组织。各专业技术委员会覆盖心血管植入物、体外诊断、医疗器械软件等具体领域。

境外企业需特别注意：中国标准的技术内容与国际标准（ISO、IEC、ASTM）高度接轨，但并非完全一致——中国版本会根据国内临床实践和监管重点有所增改。始终应以现行中文版标准为准，不能直接假设与国际版等同。

三、强制性标准：合规究竟要求什么

NMPA发布并定期更新《医疗器械产品适用强制性标准清单》（2024年修订版），按产品类别列明应适用的强制性标准，是准备任何注册申报资料前的必读文件。

注册立卷审查的要求

申请人须针对每项适用的强制性标准提供符合性证明资料。需注意：

• 证明资料不限于检验报告——对含有临床试验、生物学研究等评价性条款要求的标准，可提供相应研究资料
• 当强标发生版本更新时，NMPA在审查要求中以"注"的形式明确过渡要求，申请人须核查适用版本
• 所有适用强标均须逐一回应，不得无故省略

产品不符合强标项目时的处理

部分产品因设计或预期用途原因，无法满足强标全部条款。此时NMPA并不自动驳回，但要求申请人提供严谨的书面说明，包括：

• 明确指出不符合的具体条款
• 说明该条款不适用或无法满足的原因
• 提供等同安全性证据，证明产品不存在该标准旨在防范的危害

在申报资料中将强制性标准简单标注为"不适用"而不加任何说明，是最可靠的触发补正意见的方式之一。审评员受过专门训练，会识别这一模式。

实例：骨科植入物加速老化试验

一个常见问题：YY/T 0772.3中针对超高分子量聚乙烯（UHMWPE）骨科植入物规定的加速老化试验，能否替代注册申报中的产品稳定性研究？NMPA明确：两者是不同要求，不能相互替代。YY/T 0772.3的老化方案评价材料特性，无法模拟实际储存老化条件。产品稳定性研究（参照《无源植入性医疗器械稳定性研究指导原则》）须通过实时稳定性或基于阿列纽斯假设的加速稳定性试验，表征实际货架期退化规律。混淆两者是申报资料中的高频错误。

四、医疗器械分类体系

三类管理，各行其路

《医疗器械分类目录》

分类目录是确定产品类别的主要依据，按22个子目录覆盖全部主要器械类别。每个条目包括：一级产品类别、二级产品类别、产品描述、预期用途、管理类别及品名举例。

目录实行动态调整机制，自发布以来已多次更新（2020年第47号、2022年第25号、2022年第30号、2023年第101号公告）。调整情形包括：

• 调整子目录结构或产品类别名称
• 调整一级产品类别、二级产品类别和/或管理类别
• 增补有代表性的创新医疗器械产品
• 删除不再作为医疗器械管理的产品
• 修订产品描述、预期用途和品名举例等内容

组合产品的分类编码

有源器械整合两个独立功能模块、各模块分属不同分类编码时，实践中存在如何填写分类编码的问题。NMPA的处理原则：

• 整体产品类别按风险较高模块的管理类别判定
• 分类编码：以主体功能模块的编码填写；无法判断主体功能的，填写任一模块编码；也可填写00编码（如01-00），无需单独申请分类界定
• 示例：超声高频集成手术设备，超声模块编码01-01-01，高频模块编码01-03-01，均为三类，整体类别为三类；申报时可填01-03-01或01-00

五、未列入分类目录的新型器械

对尚未列入分类目录的新研制器械，申请人有两种选择：

1. 1
   直接按三类申报（"同三类"） 在注册申请表勾选"同三类"选项，直接向NMPA申请第三类注册。NMPA将独立判定类别，若认定为二类或一类，会通知申请人转至相应管理部门。该路径速度较快，但需承担可能被判定为低类别、需重新申报的风险。
2. 2
   申请分类界定 向NMPA提交正式的分类界定申请，获得明确的类别意见后再开展注册申报。该路径在启动全面注册工作前提供了确定性，可避免因分类错误导致的资料准备浪费。

六、药械组合产品

同时含有药品成分和器械成分的产品，在中国须经历两阶段的属性确认：

第一阶段：分类界定

该产品究竟是医疗器械还是药品？分类界定系统解决此问题。典型案例：NMPA于2022年明确，医用射线防护喷剂（含超氧化物歧化酶及姜黄素等成分，预期用途为预防和减轻医用射线对皮肤、黏膜的损伤）按第二类医疗器械管理。

第二阶段：属性界定

确认为组合产品后，属性界定程序判定产品以药为主还是以械为主，决定适用的注册路径。申请材料须包含：

• 产品名称、成分、剂量、组合方式、预期用途、接触部位/时间、产品示意图及实物照片
• 国内外同类上市产品情况（结构、组成、管理属性等）
• 产品及各组成成分的作用机制分析
• 申请人关于首要作用方式的判断及支持性依据

判定为以械为主的，按医疗器械注册；判定为以药为主的，走药品注册路径（CDE审评）。对属性界定结论有异议的，可在10个工作日内提出复议申请。

七、《医疗器械管理法》草案的重大变化

现行框架以国务院颁布的行政法规《条例》为基础。正在征求意见的《医疗器械管理法》（立法层级高于条例）是2021年以来最重要的监管立法动向。

对标准体系影响最大的，是草案第二十一条的表述：只提及国家标准，不再包含行业标准的强制性兜底条款。

现行《条例》第七条：产品须符合强制性国家标准；无国家标准的，须符合强制性行业标准。草案《管理法》删去了行业标准的兜底规定。

八、对境外制造商的实操建议

启动申报资料准备前

• 核查最新版分类目录——鉴于目录动态调整机制，超过12个月的分类意见不宜直接使用
• 下载2024年修订版强制性标准清单，将适用标准逐一对应至现有技术文件
• 核实标准版本——若强标已发布新版，NMPA可能要求按新版执行，过渡时间安排由审查要求注释说明
• 明确拟引用的推荐性标准——一旦在申报资料中声明执行，NMPA即予核查

资料准备过程中

• 逐一回应所有适用强制性标准——即便某项条款不适用，也须提供有据可查的说明
• 不要混淆不同类型的研究（如材料特性表征试验 vs. 货架期稳定性研究）
• 在申报资料中使用现行中文标准编号和名称——引用已废止的标准编号是翻译中的高频错误

新型或边界产品

• 产品不在分类目录中的，可选择"同三类"路径（速度快）或正式分类界定路径（确定性高）
• 药械组合产品须提前启动分类界定和属性界定程序——两项确认均须在正式注册前完成，将显著增加整体时间线